Company Description
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally.
The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools.
It also provides treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications.
In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient’s overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions.
Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE closure products comprising VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen.
The company sells its products through direct sales force, independent distributors, clinical specialists, and sales representatives.
Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 1971 |
| IPO Date | May 9, 1991 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 3,023 |
| CEO | Christopher Simon |
Contact Details
Address: 125 Summer Street Boston, Massachusetts 02110 United States | |
| Phone | 781 848 7100 |
| Website | haemonetics.com |
Stock Details
| Ticker Symbol | HAE |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0000313143 |
| CUSIP Number | 405024100 |
| ISIN Number | US4050241003 |
| Employer ID | 04-2882273 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Christopher A. Simon | Chief Executive Officer, President and Director |
| James C. D'Arecca CPA | Chief Financial Officer, Executive Vice President and Financial Officer |
| Michelle L. Basil Esq., J.D. | Executive Vice President, General Counsel and Secretary |
| Roy Galvin | Executive Vice President and Chief Commercial Officer |
| Frank W. Chan Ph.D. | Executive Vice President and Chief Operating Officer |
| Farris Maryanne Maunsell | Vice President, Chief Accounting Officer and Principal Accounting Officer |
| Olga Guyette | Senior Director of Investor Relations |
| Rajeev Varma | Senior Vice President of Strategy and Corporate Development |
| Laurie A. Miller | Senior Vice President and Chief Human Resources Officer |
| Dr. Jan Hartmann M.D. | Senior Vice President and Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 25, 2025 | 8-K | Current Report |
| Jun 26, 2025 | 144 | Filing |
| Jun 12, 2025 | 144 | Filing |
| Jun 6, 2025 | ARS | Filing |
| Jun 6, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jun 6, 2025 | DEF 14A | Other definitive proxy statements |
| Jun 4, 2025 | 144 | Filing |
| Jun 2, 2025 | 144 | Filing |
| May 27, 2025 | SD | Form - SD |
| May 21, 2025 | 10-K | Annual Report |